Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1996 Feb 15;154(4):457–464.

A sociobehavioural perspective on genetic testing and counselling for heritable breast, ovarian and colon cancer.

K G Macdonald 1, B Doan 1, M Kelner 1, K M Taylor 1
PMCID: PMC1487608  PMID: 8630835

Abstract

Testing for susceptibility to heritable breast, ovarian and colon cancer has unique psychosocial costs. Negative test results may not be sufficient to relieve anxiety, and positive results can cause sufficient distress to compromise patient compliance with surveillance and risk reduction measures. More needs to be learned about how sociocultural factors affect the understanding of risk, how decisions to undergo testing are made and how information about increased risk affects family dynamics. As the demand for testing and counselling grows, health care providers will be faced with new challenges and dilemmas. A better understanding of genetics by the public is needed to mitigate deterministic attitudes that can lead to the neglect of health promotion. Also of concern are the socioeconomic implications of being identified as having a high risk for heritable cancer and the dangers inherent in using genetics to explain sociological phenomena. Health care providers must take the lead in ensuring that developments in genetics are used to the benefit of all.

Full text

PDF
457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Annas G. J. Informed consent, cancer, and truth in prognosis. N Engl J Med. 1994 Jan 20;330(3):223–225. doi: 10.1056/NEJM199401203300324. [DOI] [PubMed] [Google Scholar]
  2. Biesecker B. B., Boehnke M., Calzone K., Markel D. S., Garber J. E., Collins F. S., Weber B. L. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA. 1993 Apr 21;269(15):1970–1974. [PubMed] [Google Scholar]
  3. Bloch M., Fahy M., Fox S., Hayden M. R. Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet. 1989 Feb;32(2):217–224. doi: 10.1002/ajmg.1320320215. [DOI] [PubMed] [Google Scholar]
  4. Breo D. L. Altered fates--counseling families with inherited breast cancer. JAMA. 1993 Apr 21;269(15):2017–2022. doi: 10.1001/jama.269.15.2017. [DOI] [PubMed] [Google Scholar]
  5. Charo R. A. Legal and regulatory issues surrounding carrier testing. Clin Obstet Gynecol. 1993 Sep;36(3):568–597. doi: 10.1097/00003081-199309000-00013. [DOI] [PubMed] [Google Scholar]
  6. Clarke A. Is non-directive genetic counselling possible? Lancet. 1991 Oct 19;338(8773):998–1001. doi: 10.1016/0140-6736(91)91849-p. [DOI] [PubMed] [Google Scholar]
  7. Clarke A. The genetic testing of children. Working Party of the Clinical Genetics Society (UK) J Med Genet. 1994 Oct;31(10):785–797. doi: 10.1136/jmg.31.10.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Claus E. B., Risch N., Thompson W. D. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991 Feb;48(2):232–242. [PMC free article] [PubMed] [Google Scholar]
  9. Clayton Ellen Wright. Screening and treatment of newborns. Houst Law Rev. 1992 Spring;29(1):85–148. [PubMed] [Google Scholar]
  10. Croyle R. T., Lerman C. Interest in genetic testing for colon cancer susceptibility: cognitive and emotional correlates. Prev Med. 1993 Mar;22(2):284–292. doi: 10.1006/pmed.1993.1023. [DOI] [PubMed] [Google Scholar]
  11. Daly M. B., Lerman C. Ovarian cancer risk counseling: a guide for the practitioner. Oncology (Williston Park) 1993 Nov;7(11):27-34; discussion 34, 37-8, 41. [PubMed] [Google Scholar]
  12. Draper Elaine. Genetic secrets: social issues of medical screening in a genetic age. Hastings Cent Rep. 1992 Jul-Aug;22(4 Suppl):S15–S18. [PubMed] [Google Scholar]
  13. Easton D. F., Bishop D. T., Ford D., Crockford G. P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993 Apr;52(4):678–701. [PMC free article] [PubMed] [Google Scholar]
  14. Elias S., Annas G. J. Generic consent for genetic screening. N Engl J Med. 1994 Jun 2;330(22):1611–1613. doi: 10.1056/NEJM199406023302213. [DOI] [PubMed] [Google Scholar]
  15. Eng C., Stratton M., Ponder B., Murday V., Easton D., Sacks N., Watson M., Eeles R. Familial cancer syndromes. Lancet. 1994 Mar 19;343(8899):709–713. doi: 10.1016/s0140-6736(94)91585-7. [DOI] [PubMed] [Google Scholar]
  16. Evans D. G., Fentiman I. S., McPherson K., Asbury D., Ponder B. A., Howell A. Familial breast cancer. BMJ. 1994 Jan 15;308(6922):183–187. doi: 10.1136/bmj.308.6922.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Evans D. G., Ribiero G., Warrell D., Donnai D. Ovarian cancer family and prophylactic choices. J Med Genet. 1992 Jun;29(6):416–418. doi: 10.1136/jmg.29.6.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Firth H. V., Lindenbaum R. H. UK clinicians' knowledge of and attitudes to the prenatal diagnosis of single gene disorders. J Med Genet. 1992 Jan;29(1):20–23. doi: 10.1136/jmg.29.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ganz P. A., Schag A. C., Lee J. J., Polinsky M. L., Tan S. J. Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? Cancer. 1992 Apr 1;69(7):1729–1738. doi: 10.1002/1097-0142(19920401)69:7<1729::aid-cncr2820690714>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  20. Geller G., Tambor E. S., Bernhardt B. A., Chase G. A., Hofman K. J., Faden R. R., Holtzman N. A. Physicians' attitudes toward disclosure of genetic information to third parties. J Law Med Ethics. 1993 Summer;21(2):238–240. doi: 10.1111/j.1748-720x.1993.tb01246.x. [DOI] [PubMed] [Google Scholar]
  21. Geller G., Tambor E. S., Chase G. A., Hofman K. J., Faden R. R., Holtzman N. A. Incorporation of genetics in primary care practice. Will physicians do the counseling and will they be directive? Arch Fam Med. 1993 Nov;2(11):1119–1125. doi: 10.1001/archfami.2.11.1119. [DOI] [PubMed] [Google Scholar]
  22. Geller G., Tambor E. S., Chase G. A., Holtzman N. A. Measuring physicians' tolerance for ambiguity and its relationship to their reported practices regarding genetic testing. Med Care. 1993 Nov;31(11):989–1001. doi: 10.1097/00005650-199311000-00002. [DOI] [PubMed] [Google Scholar]
  23. Geller Gail, Holtzman Neil A. Implications of the human genome initiative for the primary care physician. Bioethics. 1991 Oct;5(4):318–325. doi: 10.1111/j.1467-8519.1991.tb00172.x. [DOI] [PubMed] [Google Scholar]
  24. Gerrity M. S., DeVellis R. F., Earp J. A. Physicians' reactions to uncertainty in patient care. A new measure and new insights. Med Care. 1990 Aug;28(8):724–736. doi: 10.1097/00005650-199008000-00005. [DOI] [PubMed] [Google Scholar]
  25. Green J., Murton F., Statham H. Psychosocial issues raised by a familial ovarian cancer register. J Med Genet. 1993 Jul;30(7):575–579. doi: 10.1136/jmg.30.7.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Griffith R. S., Williams P. A. Barriers and incentives of physicians and patients to cancer screening. Prim Care. 1992 Sep;19(3):535–556. [PubMed] [Google Scholar]
  27. Hofman K. J., Tambor E. S., Chase G. A., Geller G., Faden R. R., Holtzman N. A. Physicians' knowledge of genetics and genetic tests. Acad Med. 1993 Aug;68(8):625–632. doi: 10.1097/00001888-199308000-00013. [DOI] [PubMed] [Google Scholar]
  28. Holtzman N. A. Benefits and risks of emerging genetic technologies: the need for regulation. Clin Chem. 1994 Aug;40(8):1652–1657. [PubMed] [Google Scholar]
  29. Kelly P. T. Informational needs of individuals and families with hereditary cancers. Semin Oncol Nurs. 1992 Nov;8(4):288–292. doi: 10.1016/0749-2081(92)90042-2. [DOI] [PubMed] [Google Scholar]
  30. Kerlikowske K., Brown J. S., Grady D. G. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992 Oct;80(4):700–707. [PubMed] [Google Scholar]
  31. Kessler Seymour. Psychological aspects of genetic counseling: VII. Thoughts on directiveness. J Genet Couns. 1992 Mar;1(1):9–17. doi: 10.1007/BF00960080. [DOI] [PubMed] [Google Scholar]
  32. King M. C., Rowell S., Love S. M. Inherited breast and ovarian cancer. What are the risks? What are the choices? JAMA. 1993 Apr 21;269(15):1975–1980. [PubMed] [Google Scholar]
  33. Knoppers B. M., Chadwick R. The Human Genome Project: under an international ethical microscope. Science. 1994 Sep 30;265(5181):2035–2036. doi: 10.1126/science.8091225. [DOI] [PubMed] [Google Scholar]
  34. Lantos J. Informed consent. The whole truth for patients? Cancer. 1993 Nov 1;72(9 Suppl):2811–2815. doi: 10.1002/1097-0142(19931101)72:9+<2811::aid-cncr2820721507>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  35. Lerman C., Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med. 1994 Mar 28;154(6):609–616. [PubMed] [Google Scholar]
  36. Lerman C., Daly M., Masny A., Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 1994 Apr;12(4):843–850. doi: 10.1200/JCO.1994.12.4.843. [DOI] [PubMed] [Google Scholar]
  37. Lerman C., Rimer B. K., Engstrom P. F. Cancer risk notification: psychosocial and ethical implications. J Clin Oncol. 1991 Jul;9(7):1275–1282. doi: 10.1200/JCO.1991.9.7.1275. [DOI] [PubMed] [Google Scholar]
  38. Lerman C., Trock B., Rimer B. K., Jepson C., Brody D., Boyce A. Psychological side effects of breast cancer screening. Health Psychol. 1991;10(4):259–267. doi: 10.1037//0278-6133.10.4.259. [DOI] [PubMed] [Google Scholar]
  39. Lidz C. W., Appelbaum P. S., Meisel A. Two models of implementing informed consent. Arch Intern Med. 1988 Jun;148(6):1385–1389. [PubMed] [Google Scholar]
  40. Lynch H. T., Watson P., Conway T. A., Lynch J. F., Slominski-Caster S. M., Narod S. A., Feunteun J., Lenoir G. DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med. 1993 Sep 13;153(17):1979–1987. [PubMed] [Google Scholar]
  41. Malkin D. Germline p53 gene mutations and cancer--Pandora's box or open sesame? J Natl Cancer Inst. 1994 Mar 2;86(5):326–328. doi: 10.1093/jnci/86.5.326. [DOI] [PubMed] [Google Scholar]
  42. Marteau T. M. The genetic testing of children. J Med Genet. 1994 Oct;31(10):743–743. doi: 10.1136/jmg.31.10.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Marteau T. M., van Duijn M., Ellis I. Effects of genetic screening on perceptions of health: a pilot study. J Med Genet. 1992 Jan;29(1):24–26. doi: 10.1136/jmg.29.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Naveed M., Phadke S. R., Sharma A., Agarwal S. S. Sociocultural problems in genetic counselling. J Med Genet. 1992 Feb;29(2):140–140. doi: 10.1136/jmg.29.2.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Nayfield S. G., Karp J. E., Ford L. G., Dorr F. A., Kramer B. S. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991 Oct 16;83(20):1450–1459. doi: 10.1093/jnci/83.20.1450. [DOI] [PubMed] [Google Scholar]
  46. Nelkin D., Tancredi L. Classify and control: genetic information in the schools. Am J Law Med. 1991;17(1-2):51–73. [PubMed] [Google Scholar]
  47. Punales-Morejon D., Penchaszadeh V. B. Psychosocial aspects of genetic counseling: cross-cultural issues. Birth Defects Orig Artic Ser. 1992;28(1):11–15. [PubMed] [Google Scholar]
  48. Pyeritz R. E., Tumpson J. E., Bernhardt B. A. The economics of clinical genetics services. I. Preview. Am J Hum Genet. 1987 Oct;41(4):549–558. [PMC free article] [PubMed] [Google Scholar]
  49. Quaid K. A., Morris M. Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet. 1993 Jan 1;45(1):41–45. doi: 10.1002/ajmg.1320450112. [DOI] [PubMed] [Google Scholar]
  50. Resta Robert G. The twisted helix: an essay on genetic counselors, eugenics, and social responsibility. J Genet Couns. 1992 Sep;1(3):227–243. doi: 10.1007/BF00961584. [DOI] [PubMed] [Google Scholar]
  51. Robinson A. Genetic diagnosis: present and prospects. CMAJ. 1994 Jan 1;150(1):49–52. [PMC free article] [PubMed] [Google Scholar]
  52. Rowell S., Newman B., Boyd J., King M. C. Inherited predisposition to breast and ovarian cancer. Am J Hum Genet. 1994 Nov;55(5):861–865. [PMC free article] [PubMed] [Google Scholar]
  53. Schlesselman J. J. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception. 1989 Jul;40(1):1–38. doi: 10.1016/0010-7824(89)90025-5. [DOI] [PubMed] [Google Scholar]
  54. Sharpe N. F. Informed consent and Huntington disease: a model for communication. Am J Med Genet. 1994 Apr 15;50(3):239–246. doi: 10.1002/ajmg.1320500306. [DOI] [PubMed] [Google Scholar]
  55. Sharpe N. F. Presymptomatic testing for Huntington disease: is there a duty to test those under the age of eighteen years? Am J Med Genet. 1993 Apr 15;46(2):250–253. doi: 10.1002/ajmg.1320460232. [DOI] [PubMed] [Google Scholar]
  56. Silva Mary Cipriano, Sorrell Jeanne Merkle. Enhancing comprehension of information for informed consent: a review of empirical research. IRB. 1988 Jan-Feb;10(1):1–5. [PubMed] [Google Scholar]
  57. Siminoff L. A., Fetting J. H., Abeloff M. D. Doctor-patient communication about breast cancer adjuvant therapy. J Clin Oncol. 1989 Sep;7(9):1192–1200. doi: 10.1200/JCO.1989.7.9.1192. [DOI] [PubMed] [Google Scholar]
  58. Singer Eleanor. Public attitudes toward genetic testing. Popul Res Policy Rev. 1991;10(3):235–255. doi: 10.1007/BF00141952. [DOI] [PubMed] [Google Scholar]
  59. Somer M., Mustonen H., Norio R. Evaluation of genetic counselling: recall of information, post-counselling reproduction, and attitude of the counsellees. Clin Genet. 1988 Dec;34(6):352–365. doi: 10.1111/j.1399-0004.1988.tb02893.x. [DOI] [PubMed] [Google Scholar]
  60. Sorrell J. M. Effects of writing/speaking on comprehension of information for informed consent. West J Nurs Res. 1991 Feb;13(1):110–122. doi: 10.1177/019394599101300108. [DOI] [PubMed] [Google Scholar]
  61. Spinsanti S. Obtaining consent from the family: a horizon for clinical ethics. J Clin Ethics. 1992 Fall;3(3):188–192. [PubMed] [Google Scholar]
  62. Tauber A. I., Sarkar S. The human genome project: has blind reductionism gone too far? Perspect Biol Med. 1992 Winter;35(2):220–235. doi: 10.1353/pbm.1992.0015. [DOI] [PubMed] [Google Scholar]
  63. Vernon S. W., Laville E. A., Jackson G. L. Participation in breast screening programs: a review. Soc Sci Med. 1990;30(10):1107–1118. doi: 10.1016/0277-9536(90)90297-6. [DOI] [PubMed] [Google Scholar]
  64. Wang Vivian, Marsh Frank H. Ethical principles and cultural integrity in health care delivery: Asian ethnocultural perspectives in genetic services. J Genet Couns. 1992 Mar;1(1):81–92. doi: 10.1007/BF00960087. [DOI] [PubMed] [Google Scholar]
  65. Wardle J., Pope R. The psychological costs of screening for cancer. J Psychosom Res. 1992 Oct;36(7):609–624. doi: 10.1016/0022-3999(92)90051-3. [DOI] [PubMed] [Google Scholar]
  66. Weber B. L. Susceptibility genes for breast cancer. N Engl J Med. 1994 Dec 1;331(22):1523–1524. doi: 10.1056/NEJM199412013312214. [DOI] [PubMed] [Google Scholar]
  67. Wertz D. C., Fanos J. H., Reilly P. R. Genetic testing for children and adolescents. Who decides? JAMA. 1994 Sep 21;272(11):875–881. [PubMed] [Google Scholar]
  68. Wertz D. C., Fletcher J. C. Geneticists approach ethics: an international survey. Clin Genet. 1993 Feb;43(2):104–110. doi: 10.1111/j.1399-0004.1993.tb04460.x. [DOI] [PubMed] [Google Scholar]
  69. Wertz D. C., Fletcher J. C., Mulvihill J. J. Medical geneticists confront ethical dilemmas: cross-cultural comparisons among 18 nations. Am J Hum Genet. 1990 Jun;46(6):1200–1213. [PMC free article] [PubMed] [Google Scholar]
  70. Wertz D. C., Sorenson J. R., Heeren T. C. Clients' interpretation of risks provided in genetic counseling. Am J Hum Genet. 1986 Aug;39(2):253–264. [PMC free article] [PubMed] [Google Scholar]
  71. Whittaker L. A. The implications of the Human Genome Project for family practice. J Fam Pract. 1992 Sep;35(3):294–301. [PubMed] [Google Scholar]
  72. Wilfond B. S., Nolan K. National policy development for the clinical application of genetic diagnostic technologies. Lessons from cystic fibrosis. JAMA. 1993 Dec 22;270(24):2948–2954. [PubMed] [Google Scholar]
  73. Wooster R., Neuhausen S. L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994 Sep 30;265(5181):2088–2090. doi: 10.1126/science.8091231. [DOI] [PubMed] [Google Scholar]
  74. Yeaton W. H., Smith D., Rogers K. Evaluating understanding of popular press reports of health research. Health Educ Q. 1990 Summer;17(2):223–234. doi: 10.1177/109019819001700208. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES